-
Press ReleaseNovartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
-
Press ReleaseNovartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
-
Press ReleaseNovartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
-
Press ReleaseNovartis appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch retires after 22 years with the company
-
Press ReleaseNovartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance
-
Press ReleaseNovartis verzeichnet ein starkes zweites Quartal mit zweistelligem Umsatzwachstum und erhöhter Kerngewinnmarge; Prognose für das operative Kernergebnis im Geschäftsjahr 2025 angehoben
-
Press ReleaseNovartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
-
Press ReleaseNovartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH
-
Press ReleaseNovartis announces commencement of tender offer to acquire Regulus Therapeutics
-
Press ReleaseNovartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure
-
Press ReleaseNovartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1
-
Press ReleaseNovartis setzt die starke Dynamik fort mit zweistelligem Umsatzwachstum, robusten Margensteigerungen und mehreren Zulassungen im ersten Quartal